These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
130 related items for PubMed ID: 11273779
1. Regression of human mammary adenocarcinoma by systemic administration of a recombinant gene encoding the hFlex-TRAIL fusion protein. Wu X, He Y, Falo LD, Hui KM, Huang L. Mol Ther; 2001 Mar; 3(3):368-74. PubMed ID: 11273779 [Abstract] [Full Text] [Related]
2. Cancer gene therapy using a novel secretable trimeric TRAIL. Kim CY, Jeong M, Mushiake H, Kim BM, Kim WB, Ko JP, Kim MH, Kim M, Kim TH, Robbins PD, Billiar TR, Seol DW. Gene Ther; 2006 Feb; 13(4):330-8. PubMed ID: 16195699 [Abstract] [Full Text] [Related]
9. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Pollack IF, Erff M, Ashkenazi A. Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907 [Abstract] [Full Text] [Related]
10. Long-term tumor-free survival from treatment with the GFP-TRAIL fusion gene expressed from the hTERT promoter in breast cancer cells. Lin T, Huang X, Gu J, Zhang L, Roth JA, Xiong M, Curley SA, Yu Y, Hunt KK, Fang B. Oncogene; 2002 Nov 14; 21(52):8020-8. PubMed ID: 12439752 [Abstract] [Full Text] [Related]
11. Induction of potent TRAIL-mediated tumoricidal activity by hFLEX/Furin/TRAIL recombinant DNA construct. Wu X, Hui KM. Mol Ther; 2004 May 14; 9(5):674-81. PubMed ID: 15120328 [Abstract] [Full Text] [Related]
12. In vitro enhanced cytotoxicity of tumor-infiltrating lymphocytes transfected with tumor necrosis factor-related apoptosis-inducing ligand and/or interleukin-2 gene in human renal cell carcinoma. Tian JQ, Wang ZP, Rodriguez R, Fu JS, Lu JZ, Ma BL. Urology; 2006 May 14; 67(5):1093-8. PubMed ID: 16635513 [Abstract] [Full Text] [Related]
14. Combined TRAIL and Bax gene therapy prolonged survival in mice with ovarian cancer xenograft. Huang X, Lin T, Gu J, Zhang L, Roth JA, Stephens LC, Yu Y, Liu J, Fang B. Gene Ther; 2002 Oct 14; 9(20):1379-86. PubMed ID: 12365003 [Abstract] [Full Text] [Related]
15. The secretable form of trimeric TRAIL, a potent inducer of apoptosis. Kim MH, Billiar TR, Seol DW. Biochem Biophys Res Commun; 2004 Sep 03; 321(4):930-5. PubMed ID: 15358116 [Abstract] [Full Text] [Related]
16. Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. Shi J, Zheng D, Liu Y, Sham MH, Tam P, Farzaneh F, Xu R. Cancer Res; 2005 Mar 01; 65(5):1687-92. PubMed ID: 15753363 [Abstract] [Full Text] [Related]
18. Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Bernt KM, Ni S, Tieu AT, Lieber A. Cancer Res; 2005 May 15; 65(10):4343-52. PubMed ID: 15899826 [Abstract] [Full Text] [Related]
20. Enhanced TRAIL sensitivity by E1A expression in human cancer and normal cell lines: inhibition by adenovirus E1B19K and E3 proteins. Hu B, Zhu H, Qiu S, Su Y, Ling W, Xiao W, Qi Y. Biochem Biophys Res Commun; 2004 Dec 24; 325(4):1153-62. PubMed ID: 15555548 [Abstract] [Full Text] [Related] Page: [Next] [New Search]